Kasugamycin potentiates rifampicin and limits emergence of resistance in Mycobacterium tuberculosis by specifically decreasing mycobacterial mistranslation

ELife
Swarnava ChaudhuriBabak Javid

Abstract

Most bacteria use an indirect pathway to generate aminoacylated glutamine and/or asparagine tRNAs. Clinical isolates of Mycobacterium tuberculosis with increased rates of error in gene translation (mistranslation) involving the indirect tRNA-aminoacylation pathway have increased tolerance to the first-line antibiotic rifampicin. Here, we identify that the aminoglycoside kasugamycin can specifically decrease mistranslation due to the indirect tRNA pathway. Kasugamycin but not the aminoglycoside streptomycin, can limit emergence of rifampicin resistance in vitro and increases mycobacterial susceptibility to rifampicin both in vitro and in a murine model of infection. Moreover, despite parenteral administration of kasugamycin being unable to achieve the in vitro minimum inhibitory concentration, kasugamycin alone was able to significantly restrict growth of Mycobacterium tuberculosis in mice. These data suggest that pharmacologically reducing mistranslation may be a novel mechanism for targeting bacterial adaptation.

References

Oct 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·A W CurnowD Söll
Jun 3, 1998·Applied and Environmental Microbiology·J B AndersenS Molin
Dec 3, 1999·Science·M Ibba, D Söll
Oct 3, 2002·Biochemical and Biophysical Research Communications·Isabella Moll, Udo Bläsi
Jun 15, 2006·Expert Review of Anti-infective Therapy·Francesco Scaglione, Luca Paraboni
Sep 26, 2006·Nature Structural & Molecular Biology·Barbara S SchuwirthAntón Vila-Sanjurjo
Feb 19, 2008·Journal of Molecular Biology·Kelly Sheppard, Dieter Söll
Oct 24, 2008·Proceedings of the National Academy of Sciences of the United States of America·Benfang RuanDieter Söll
Dec 19, 2008·Nature·Hani S Zaher, Rachel Green
May 4, 2010·The Journal of Antimicrobial Chemotherapy·Crystal M Darby, Carl F Nathan
Jun 10, 2010·Annual Review of Microbiology·Kim Lewis
Jul 17, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·D A Mitchison
Jan 5, 2013·Science·Yuichi WakamotoJohn D McKinney
Jun 19, 2013·Proceedings of the National Academy of Sciences of the United States of America·Feng WangPeter G Schultz
Aug 1, 2013·The Journal of Infectious Diseases·Jotam G PasipanodyaTawanda Gumbo
Sep 11, 2013·Nature Reviews. Microbiology·Nathalie Q BalabanJohn D McKinney
Dec 18, 2013·Nature Reviews. Microbiology·Daniel N Wilson
Jan 8, 2014·Proceedings of the National Academy of Sciences of the United States of America·Babak JavidEric J Rubin
Apr 29, 2014·Cell·Etienne Maisonneuve, Kenn Gerdes
Jul 16, 2014·Trends in Biochemical Sciences·Liuís Ribas de PouplanaBabak Javid
May 15, 2015·Science Translational Medicine·Pia Abel Zur WieschTed Cohen
Jun 25, 2015·Microbiology Spectrum·Bree B AldridgeSarah M Fortune
Sep 8, 2015·Nature Medicine·Brendan PrideauxVéronique Dartois
Jun 4, 2016·Antibiotics·Christian MüllerIsabella Moll
Jul 1, 2016·Proceedings of the National Academy of Sciences of the United States of America·Kirill RichardsonBree B Aldridge
Dec 20, 2016·Nature Chemical Biology·Huiqing ZhengRobert B Abramovitch
Jan 13, 2017·PloS One·Christian LangeJörg Soppa
Feb 12, 2017·Science·Irit Levin-ReismanNathalie Q Balaban
Feb 25, 2017·Microbiology Spectrum·Ben Gold, Carl Nathan
Apr 12, 2017·Proceedings of the National Academy of Sciences of the United States of America·Catherine VilchèzeWilliam R Jacobs
Jun 1, 2017·Proceedings of the National Academy of Sciences of the United States of America·Kohta SaitoCarl F Nathan

❮ Previous
Next ❯

Citations

Jul 11, 2019·Open Biology·Anne WitzkyMichael Ibba
Feb 12, 2020·Antimicrobial Agents and Chemotherapy·Martin GengenbacherVéronique Dartois
Jun 21, 2019·Current Pharmaceutical Design·Prasad MinakshiGaya Prasad
Nov 13, 2019·Cell Chemical Biology·Xin WangJoel S Freundlich
Aug 5, 2021·Molecular Aspects of Medicine·Niraj KumarPrem S Kaushal
Aug 18, 2021·The Journal of Antibiotics·Rebekah A AdamsMark P Brynildsen
Jan 23, 2022·Proceedings of the National Academy of Sciences of the United States of America·Yan ZhangAlexander S Mankin

❮ Previous
Next ❯

Methods Mentioned

BETA
aminoacylation
PCR

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
Babak JavidEric J Rubin
Revista brasileira de tuberculose e doenças torácicas
E R LONG
Revista española de tuberculosis
F R de PARTEARROYO, A FRANCO MORANTE
© 2022 Meta ULC. All rights reserved